Gilenya was first approved in 2010 and has been a big brand for Novartis, although it is facing strong competition from newer drugs such as Roche's Ocrevus (ocrelizumab), Merck KGaA's Mavenclad ...

Gilenya is Novartis' third-biggest product and the top seller in its neuroscience franchise, bringing in revenues of almost $2.8 billion in 2021, although sales have started to decline due to ...

The risk of disease activity in going to a less effective DMT was higher in younger adults and those having prior ...

You disconnect your cell phone from its charger as you get ready for a busy day. But even though it has been connected all night, the battery is only partially charged. You look at ...

In 2010, multiple sclerosis [MS] had its first oral drug, fingolimod [Gilenya], [approved]. I happened to meet with one of my mentors, Timothy Vollmer, MD, who’s now retired, and we started ...

Winter is the worst season of columnist Leigh Anne Nelson's discontent, as her MS has suffered with heavy snowfalls, ice ...

Natural treatments for multiple sclerosis can play a role in managing MS symptoms and possibly slowing the advance of the condition. Options include diet, exercise, and stress management strategies.

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 176,000 newsletter subscribers for 21 days.